Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
pubmed.ncbi.nlm.nih.gov/21795440/ Richie JP Jr et al
Phase III RECONNECT Trials (HSDD in Premenopausal Women) The pivotal Phase III program consisted of two identically designed trials RECONNECT Study 301 and Study 302 conducted across North America: RECONNECT Study 301 (n=684) : Design : Randomized, double-blind, placebo-controlled, 24-week study Population : Premenopausal women with generalized, acquired HSDD Intervention : Bremelanotide 1.75 mg subcutaneous injection, self-administered as needed (at least 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than 8 doses per month) Co-primary endpoints : Change from baseline in Female Sexual Function Index-desire domain (FSFI-D) score and Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score (distress due to low sexual desire) Results : Statistically significant improvement in FSFI-D score (+0.5 vs
Can dermal fillers be used with AquaGold
Furthermore, there is a correlation between elevated mortality and severe CVD symptoms and indications and a rise in TMAO levels
US$ 21.16
US$ 21.69
US$ 21.78
US$ 29.24
US$ 21.53
US$ 27.10
US$ 24.58
US$ 22.94
US$ 25.50
US$ 29.40
US$ 20.86
US$ 25.95
